Advanced Gastroesophageal Cancer
Publication Date: January 5, 2023
Key Points
Key Points
- Gastroesophageal cancers are among the most prevalent gastrointestinal malignancies worldwide. In 2020, there were over 1 million new cases and 769,000 deaths due to gastric cancer.
- Most gastric and gastrointestinal junction tumors are adenocarcinoma.
- Targeted cancer therapies and immunotherapy are more effective in subgroups of gastroesophageal cancer patients who possess certain biomarkers such as programmed death-ligand 1 (PD-L1) protein expression.
Treatment
...Treatment...
...1. Immunotherapy and Targeted Thera...
...First...
...1.1For HER2-negative patients with gast...
...tion 1.2For HER2-negative patients w...
...endation 1.3For patients with ESCC a...
...mendation 1.4For patients with ESCC, and PD-L...
...endation 1.5For patients with HER2-p...
...Second- or Thir...
...tion 2.1For patients with advanced gastroesopha...
...tion 2.2For HER2-positive patients with...